Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Patients With Breast Cancer and BRCA1, BRCA2, CHEK2, or PALB2 Germline Pathogenic Variants May Benefit From Enhanced Surveillance

A Look Back at 2022 FDA Approvals in Oncology

Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies

Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer

Sacituzumab Govitecan Receives Indication for Unresectable, Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Patients With Breast Cancer and BRCA1, BRCA2, CHEK2, or PALB2 Germline Pathogenic Variants May Benefit From Enhanced Surveillance

A Look Back at 2022 FDA Approvals in Oncology

Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies

Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer

Sacituzumab Govitecan Receives Indication for Unresectable, Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Patients With Breast Cancer and BRCA1, BRCA2, CHEK2, or PALB2 Germline Pathogenic Variants May Benefit From Enhanced Surveillance

A Look Back at 2022 FDA Approvals in Oncology

Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies

Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer

Sacituzumab Govitecan Receives Indication for Unresectable, Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Related Content

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

The FDA has approved sacituzumab govitecan-hziy for patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.

Patients With Breast Cancer and BRCA1, BRCA2, CHEK2, or PALB2 Germline Pathogenic Variants May Benefit From Enhanced Surveillance

Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

A Look Back at 2022 FDA Approvals in Oncology

Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.

Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer

Jamie Carroll, APRN, CNP, MSN, offers her perspective on emerging data from the 2022 San Antonio Breast Cancer Symposium.